

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Marc Bosiers

Page 1/12

Tuesday, January 30, 2018

## ROOM 3 - TECHNICAL FORUM

- 09:00 – 11:00**      **Management of carotid artery disease: Remaining controversies and challenges ahead**  
*MODERATOR:*  
Marc van Sambeek  
William Gray  
*PANEL:*  
Carlo Setacci  
Stanislaw Bartus  
Steve Ramee
- 09:00 – 09:07      Randomised data in carotid artery stenting: current evidence and future perspectives  
Marco Roffi
- 09:07 – 09:12      Despite Level 1 and other evidence, the future outlook for carotid stenting is bright  
Frank Veith
- 09:12 – 09:19      The future of carotid stenting – Proximal protection and mesh-covered stents are the answer  
Stanislaw Bartus
- 09:19 – 09:44      Live case transmission from Berlin  
Sankt-Gertrauden-Hospital Berlin - Live case center
- 09:44 – 09:51      1-year results of a new mesh-covered carotid stent: SCAFFOLD trial  
William Gray
- 09:51 – 09:58      The CLEAR-ROAD study: a physician-initiated study investigating the RoadSaver stent in carotid lesions (final 12-month results)  
**Marc Bosiers**
- 09:58 – 10:05      PrOspective multiCentrE study of cArotid artery steNting Using MER Stent – the OCEANUS study  
Piotr Pieniazek
- 10:05 – 10:12      Comparative analysis of new mesh-covered stent designs using MRI parameters  
Maria Antonella Ruffino
- 10:12 – 10:19      Plaque protrusion during carotid artery stenting: risk factors determined by MR plaque imaging  
Katsutoshi Takayama

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 2/12

## Tuesday, January 30, 2018

- |               |   |
|---------------|---|
| 10:19 – 10:26 | ROADSTER 2 trial: Transcervical access with reversed flow circuit for proximal protection during CAS. What have we learned so far?<br>Peter Schneider |
| 10:26 – 10:33 | Transcervical carotid stenting (TECAR) with flow reversal vs. CEA in highly symptomatic patients<br>Ralf Kolvenbach                                   |
| 10:33 – 11:00 | THE GREAT DEBATE: HOW SHOULD WE HANDLE ASYMPTOMATIC CAROTID STENOSES?   |
| 10:33 – 10:40 | Carotid repair is best for asymptomatic severe carotid stenosis because medical management alone does not work<br>Peter Schneider                     |
| 10:40 – 10:47 | When better NOT to treat asymptomatic carotid stenosis<br>Martin Storck   |
| 10:47 – 10:54 | ACST-2, over 2500 patients randomised; what do we know?<br>Alison Halliday  |
| 10:54 – 11:00 | Discussion and conclusion   |

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Marc Bosiers

Page 3/12

Tuesday, January 30, 2018

## ROOM 1 - MAIN ARENA 1

- 09:30 – 11:00**      **Latest results with new technologies for femoropopliteal obstructions: drug-eluting devices, atherectomy and new implants**  
*MODERATOR:*  
Dierk Scheinert  
*PANEL:*  
Marianne Brodmann  
Thomas Zeller  
Steven Kum  
Wei Guo
- 09:30 – 09:35      EFFPAC–RCT: Final 6-months results with the Luminor DCB in femoropopliteal lesions  
Dierk Scheinert
- 09:35 – 09:40      ILLUMENATE EU RCT: 2-year results with the Stellarex DCB in femoropopliteal lesions  
Marianne Brodmann
- 09:40 – 09:45      FIRST TIME DATA RELEASE: CONSEQUENT RCT: 2-year results with the SeQuent Please OTW DCB  
Thomas Albrecht
- 09:45 – 09:50      FIRST TIME DATA RELEASE: IN.PACT Japan RCT of DCB vs. PTA: 2-year results  
Osamu Iida
- 09:50 – 09:55      FIRST TIME DATA RELEASE: ILLUMENATE GLOBAL: 2-year results of the Stellarex DCB in femoropopliteal lesions  
Thomas Zeller
- 09:55 – 10:00      DANCE trial (ATX and PTA groups) – 2-year results  
George Adams
- 10:00 – 10:05      Long term durability of DCB treatment in the SFA: 4-year results of the IN.PACT SFA study  
John Laird
- 10:05 – 10:10      Outcomes of DCB use in real-world patients: 2-year results from the IN.PACT global registry  
Marianne Brodmann
- 10:10 – 10:15      FIRST TIME DATA RELEASE: LUTONIX long lesion study: 2-year outcomes  
Martin Banyai

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 4/12

## Tuesday, January 30, 2018

- |               |  |
|---------------|--|
| 10:15 – 10:20 | FIRST TIME DATA RELEASE: COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions<br>Dierk Scheinert      |
| 10:20 – 10:25 | FIRST TIME DATA RELEASE: Outcomes of DCB use in femoropopliteal lesions of patients with CLI (RCC4/5): Subgroup analysis of IN.PACT global study<br>Michel Reijnen |
| 10:25 – 10:35 | PROMISE AND LIMITATIONS OF DCB – WHAT HAVE WE LEARNED?   |
| 10:25 – 10:30 | DCB from a preclinical perspective: The relevance of paclitaxel dose and coating integrity<br>Juan Fernando Granada Solis  |
| 10:30 – 10:35 | DCB from a clinical perspective: What is proven and where are the open questions and limitations?<br><b>Marc Bosiers</b>   |
| 10:35 – 10:40 | Panel discussion   |
| 10:40 – 10:45 | Update on the TOBA studies in the femoropopliteal arteries<br>Christian Wissgott   |
| 10:45 – 10:50 | FIRST TIME DATA RELEASE: LOCOMOTIVE All Comers Study with the VascuFlex Multi-LOC spot stenting device: 12-month results<br>Klaus Amendt                           |
| 10:50 – 10:55 | FIRST TIME DATA RELEASE: 1-year results from the MIMICS-2 Study; US, German, and Japanese experience with the BioMimics 3D stent<br>Thomas Zeller                  |
| 10:55 – 11:00 | Discussion and conclusion  |

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 5/12

Tuesday, January 30, 2018

## ROOM 1 - MAIN ARENA 1

11:00 – 12:30	<b>SYMPOSIUM: Patient first: “Leave the right thing behind”. Debating evidence to provide the answers</b> supported with an educational grant from COOK Medical <i>MODERATOR:</i> Iris Baumgartner-Peuker <i>PANEL:</i> Thomas Zeller Fabrizio Fanelli Aloke Finn <b>Marc Bosiers</b>
11:00 – 11:05	Introduction Iris Baumgartner-Peuker
11:05 – 11:13	XPEDITE study Thomas Zeller
11:13 – 11:21	DCB + BMS is not a DES Fabrizio Fanelli
11:21 – 11:41	Live case transmission from Leipzig University Hospital Leipzig, Dep. Angiology - Live case center
11:41 – 11:49	Understanding restenosis in the SFA Aloke Finn
11:49 – 11:57	First results of the ZILVERPASS study <b>Marc Bosiers</b>
11:57 – 12:17	Live case transmission from Jena University Hospital Jena - Live case center
12:17 – 12:25	The importance of scientific evidence Iris Baumgartner-Peuker
12:25 – 12:30	Summing up on symposium discussion and debate Iris Baumgartner-Peuker

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 6/12

Tuesday, January 30, 2018

## ROOM 5 - GLOBAL EXPERT EXCHANGE

- 12:35 – 13:20**      **LUNCH SYMPOSIUM: DCB or stent? The latest data to influence your decision**  
supported with an educational grant from iVascular  
*MODERATOR:*  
Koen Deloose
- 12:35 – 12:43      Luminor DCB makes it different and favourable in CLI (LUMINOR registry, 12-month data)  
Vicente Riambau
- 12:43 – 12:51      Is there still any space left for DES? (ANGIOLITE BTK trial, 6-month data)  
Peter Goverde
- 12:51 – 12:58      Discussion: BTK
- 12:58 – 13:06      Is Luminor DCB the best choice for femoropopliteal lesions? (EFFPAC-RCT, 6-month data)  
Ulf Teichgräber
- 13:06 – 13:14      Or is the iVolution stent a better alternative? (EVOLUTION study, 12-month data)  
**Marc Bosiers**
- 13:14 – 13:20      Femoropopliteal arteries discussion

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

## LEIPZIG INTERVENTIONAL COURSE

# L I N C



Marc Bosiers

Page 7/12

Wednesday, January 31, 2018

### ROOM 5 - GLOBAL EXPERT EXCHANGE

- 10:45 – 12:30**      **Deep dive session: Lower limb interventions (part II) – Focus on Combination therapies and new implants**  
*MODERATOR:*  
Giancarlo Biamino  
Krishna Rocha-Singh  
*PANEL:*  
Hiroyoshi Yokoi
- 10:45 – 10:50      Clinical plasticity of PLLA – Novel BioResorbable vascular platforms from India  
Arne Schwindt
- 10:50 – 10:55      FIRST TIME DATA RELEASE: Outcomes at 2 years in stented vs. non-stented patients post-DCB: A subanalysis from the IN.PACT Global study  
Gary Ansel
- 10:55 – 11:00      FIRST TIME DATA RELEASE: Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions  
Dierk Scheinert
- 11:00 – 11:30      Live case transmission from Leipzig  
University Hospital Leipzig, Dep. Angiology - Live case center
- 11:30 – 11:35      Directional Atherectomy and Anti-Restenotic Therapy (DAART) in multilevel disease  
Carlos Abel Gutierrez Diaz
- 11:35 – 11:40      Combination therapy with atherectomy followed by DCB: 1-year outcomes with Lutonix DCB and 1-year outcomes with IN.PACT DCB  
Louis Lopez
- 11:40 – 11:45      12-month and preliminary 24-month outcomes of combining a DCB with a modern generation of nitinol stent in femoropopliteal lesions: analysis of the BIOLUX 4 EVER study  
Lieven Maene
- 11:45 – 11:50      Short-term results of the RAPID Randomised trial of the Legflow® paclitaxel-eluting balloon with supra stenting vs. supra stenting alone for the treatment of intermediate and long superficial femoral artery lesions  
Daniel van den Heuvel

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 8/12

## Wednesday, January 31, 2018

11:50 – 11:55	Combination of Supera DCB in revascularisation of long femoropopliteal occlusions. Single center experience Anish Thomas
11:55 – 12:00	12-month outcomes in the EVOLUTION study: Investigating the iVolution stent in femoropopliteal lesions <b>Marc Bosiers</b>
12:00 – 12:05	Impact of Zilver PTX after stent implantation for femoropopliteal lesions for 2-year follow up. How to maximize performance of Zilver PTX Eiji Ojima
12:05 – 12:10	The clinical comparison of Zilver PTX and Innova for femoropopliteal lesions in Japanese single center Kenji Ogata
12:10 – 12:15	The Supera stent in retrograde vascular access for SFA ostium treatment: The SUPRA-FAST registry Vincenzo Pestrighella
12:15 – 12:20	Laser and DCB for SFA ISR: follow-up of a single center cohort up to 5 years Jos van den Berg
12:20 – 12:25	LIBERTY 360: Predictors of 1-year outcomes of endovascular device interventions in patients with symptomatic lower extremity peripheral artery disease William Gray
12:25 – 12:30	Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.



# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 9/12

Wednesday, January 31, 2018

## ROOM 4 - DISCUSSION FORUM

- 12:35 – 13:20**      **Lunch symposium: Drug-coated balloons for peripheral interventions: a 360° virtual reality experience**  
supported with an educational grant from Cardionovum  
*MODERATOR:*  
Peter Goverde  
Dierk Scheinert
- 12:35 – 12:38      Introduction
- 12:38 – 12:45      SAFEPAX®: What's new in the 3rd generation paclitaxel balloon matrix coating?  
Eric Ducasse
- 12:45 – 12:55      How can we improve treatment of long femoropopliteal lesions with DCB?  
**Marc Bosiers**
- 12:55 – 13:05      Recorded case presentation: let's do it together: experience the future of "medicine in virtual reality"  
  
Enrico Marone
- 13:05 – 13:15      Recorded case presentation: how can we protect the (CLI) patients to the potential risk of microembolisation?  
Koen Deloose
- 13:15 – 13:20      Conclusions and closing remarks

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Marc Bosiers

Page 10/12

Wednesday, January 31, 2018

## ROOM 1 - MAIN ARENA 1

### 16:30 – 18:00 **The last frontiers: Endovascular therapy of the common femoral artery and the popliteal segment**

*MODERATOR:*

**Marc Bosiers**

Lawrence Garcia

*PANEL:*

Chris Metzger

Ulrich Beschorner

Ralph-Ingo Rückert

Martin Malina

Darren Schneider

16:30 – 16:37 Is it now time for endovascular techniques to conquer the CFA?  
Martin Malina

16:37 – 16:42 Complex stenting of the common femoral artery  
Yann Gouëffic

16:42 – 16:47 Recanalisation of femoral bifurcations using the Culotte stent technique  
Erwin Blessing

16:47 – 16:52 The VMI-CFA study: A physician-initiated study investigating the Supera stent in the common femoral artery (preliminary 6-month results)  
Koen Deloose

16:52 – 17:15 Live case transmission from Bad Krozingen  
Heartcenter Bad Krozingen - Live case center

17:15 – 17:20 Drug-eluting treatments of the common femoral artery – the last frontier  
Konstantinos Katsanos

17:20 – 17:25 Combined use of directional atherectomy and DCB for the treatment of the CFA: immediate and one-year outcomes  
Angelo Cioppa

17:25 – 17:50 Live case transmission from Leipzig  
University Hospital Leipzig, Dep. Angiology - Live case center

17:50 – 17:55 DCB for popliteal artery stenosis: Update from the IN.PACT Flexion trial  
**Marc Bosiers**

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Marc Bosiers

Page 11/12

**Wednesday, January 31, 2018**

17:55 – 18:00      Results from the 100 patients of the prospective TIGRIS Vienna study  
Martin Werner

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Marc Bosiers

Page 12/12

Thursday, February 01, 2018

## ROOM 1 - MAIN ARENA 1

- 11:00 – 12:30**      **The remaining challenges: Long lesions and in-stent-restenosis (ISR)**  
*MODERATOR:*  
George Adams  
Dai-Do Do  
*PANEL:*  
Torsten Fuß  
Jos van den Berg  
Hans Krankenberg  
Sabine Steiner  
Chris Metzger
- 11:00 – 11:06      Endovascular treatment of severe TASC C & D lesion with Gore® Viabahn endoprosthesis  
Michele Antonello
- 11:06 – 11:11      Comparing endoluminal to open fempop bypasses: Final 2-year results of the SUPER B trial  
Michel Reijnen
- 11:11 – 11:17      2-year results of a novel Bi-Directional SFA stent design: A comparative study of safety and efficacy  
Hans Krankenberg
- 11:17 – 11:42      Live case transmission from Leipzig  
University Hospital Leipzig, Dep. Angiology - Live case center
- 11:42 – 11:48      The ZILVERPASS study: a randomised study comparing ZILVER PTX stenting with bypass in femoropopliteal lesions (preliminary 12-month results)  
**Marc Bosiers**
- 11:48 – 11:53      2-year results of the COPA CABANA RCT of DCB vs. PTA for femoropopliteal ISR  
Gunnar Tepe
- 11:53 – 11:59      New evidence from Laser + DCB in ISR  
Ehrin Armstrong
- 11:59 – 12:24      Live case transmission from Bad Krozingen  
Heartcenter Bad Krozingen - Live case center
- 12:24 – 12:30      “Crush stenting” – an alternative approach to manage occluded femoropopliteal stents  
Stefan Müller-Hülsbeck

**We are asking all faculty members to strictly respect the given time limits.**